Mouse Monoclonal NTRK2 Antibody

+ +

•  

   
     Western blot analysis of lysate from human brain tissue lysate,  using NTRK2 Antibody(Cat.  #P32979). P32979 was diluted at 1:1000.  A goat anti-mouse IgG H&L(HRP) at 1:10000 dilution was used as the secondary antibody. Lysate at 20μg.    

•  

   
     Overlay histogram showing SH-SY5Y cells stained with P32979 (green line).  The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min.  The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (P32979,  1:25 dilution) for 60 min at 37ºC.  The secondary antibody used was Goat-Anti-Mouse IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(NA168821)) at 1/400 dilution for 40 min at 37ºC.  Isotype control antibody (blue line) was mouse IgG1 (1μg/1x10^6 cells) used under the same conditions.  Acquisition of >10, 000 events was performed.    

•  

   
     P32979 staining NTRK2 in human brain sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed,  paraffin-embedded sections).  Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6).  Samples were incubated with primary antibody (1/25) for 1 hours at 37°C.  A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.    

The NTRK2 antibody is a crucial tool for studying the neurotrophic tyrosine receptor kinase 2 (NTRK2), also known as TrkB, a transmembrane receptor encoded by the *NTRK2* gene. NTRK2 binds brain-derived neurotrophic factor (BDNF) and plays a pivotal role in neuronal survival, synaptic plasticity, and cognitive functions. Dysregulation of NTRK2 signaling is implicated in neurological disorders (e.g., Alzheimer’s disease, depression, epilepsy) and cancers, particularly those with *NTRK2* fusion events that drive oncogenic signaling.

NTRK2 antibodies are widely used in research and diagnostics to detect receptor expression, activation status (e.g., phosphorylated TrkB), and subcellular localization. They enable techniques like Western blot, immunohistochemistry (IHC), and immunofluorescence (IF) to explore NTRK2's role in disease mechanisms or therapeutic responses. In oncology, these antibodies help identify tumors with NTRK2 alterations, guiding targeted therapies like TRK inhibitors (e.g., larotrectinib).

Challenges include ensuring specificity, as NTRK2 shares homology with other Trk receptors (TrkA, TrkC), and distinguishing between full-length receptors and truncated isoforms. Commercial antibodies vary in clonal origin, epitope recognition, and validation standards, necessitating careful selection based on experimental needs. Recent advances in antibody engineering have improved sensitivity for detecting low-abundance NTRK2 in complex tissues, supporting both basic research and clinical applications in precision medicine.